Apyx Medical Q2 revenue down 8% YoY; narrows 2022 guidance

Apyx Medical Corp

2022-Q2 EPS reported -$0.33 revenue$22,785,000

Total revenue $10.3M (-8% YoY); Advanced Energy revenue $8.4M (-16% YoY), OEM $1.9M (+55%).
Net loss $5.4M ($0.16 loss per share) vs $4.0M loss in Q2 2021; Adj. EBITDA loss $3.4M vs $2.4M.
Full-year revenue guidance narrowed to $51-56.4M (prev $52.5-59M); net loss guidance widened to $20.1-16.6M.
FDA granted 510(k) clearance for Renuvion Dermal Handpiece (wrinkles) and APR Handpiece (lax skin).
International Advanced Energy generator and handpiece sales fell >45% and >30% YoY respectively.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.